ANTIPLATELET THERAPY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY - UNEVENNESS OF DAILY CLINICAL PRACTICE.
Acta Clin Croat
; 60(3): 540-543, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-35282474
ABSTRACT
Antiplatelet therapy is an integral part of optimal medicamentous therapy in patients with coronary artery disease. The strategy of antiplatelet/anticoagulant therapy is adjusted (combination of drugs, dosing and duration of therapy) depending on the stage of the disease (acute coronary syndrome with percutaneous coronary intervention, chronic coronary syndrome, or coronary surgical revascularization) and comorbidity of each patient (e.g., atrial fibrillation, left ventricular thrombus, etc.). Guidelines and clinical practice in particular are not uniform and specific regarding dual antiplatelet therapy in patients undergoing coronary artery bypass grafting, especially in the setting of chronic coronary syndrome.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Atrial Fibrillation
/
Coronary Artery Disease
/
Percutaneous Coronary Intervention
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Acta Clin Croat
Journal subject:
MEDICINA
Year:
2022
Document type:
Article